Keyword: Cadila Healthcare
Gilead out-licenses COVID-19 therapy remdesivir. Legend Biotech guns for $100 million Nasdaq IPO. Takeda eyes 12 new drug launches by 2024.
The FDA is considering a "phased approach" to restarting on-site inspections of domestic and foreign drug manufacturing facilities.
A consortium of major Indian pharmas are calling on the FDA to allow "virtual" facility checks as long as the agency's inspection lockdown continues.
A COVID-19 lockdown at a major Indian manufacturing hub has left facilities shuttered or hobbled in a hit to the global drug supply chain.
The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.
Cadila's facility in St. Louis was cited by the FDA for observations after the company’s Moraiya plant was tagged by the agency last month.
India’s Cadila found a ray of sunshine in the fact that the FDA issued 14 observations during an inspection of its formulation plant in Moraiya.
A Takeda founder descendant blasts the Shire deal, as the company moves its U.S. HQ closer to Shire; Sanofi revamps two global units.
Cadila's Liva subsidiary was hit with a Form 483 by the FDA following an inspection of its plant in Vadodara, India.
Indian drugmaker Cadila Healthcare said a recent FDA inspection of its facility at Changodar, Ahmedabad, resulted in no observations.